Fig. 1: Clinical outcomes.
A Schema of a clinical trial. B Overall survival of clinical trial patients from the date of enrollment estimated by the Kaplan–Meier method (n = 19). C Progression-free survival of clinical trial patients from the date of enrollment by the Kaplan–Meier method (n = 18). D Waterfall plot depicting the relative change in tumor volume following two cycles of neoadjuvant atezolizumab stratified by PD-L1 status, smoking status, and histology (n = 18). The bars at the top of the plot represent smoking status, histology, and PD-L1 tumor proportion score for each patient. E Axial fused PET/CT images from a patient with squamous cell carcinoma with marked response following two cycles induction atezolizumab. Pre-treatment tumor measuring 4.1 cm with SUVmax 24.9 is shown in the left panel, and a post-treatment tumor measuring 2.5 cm with SUVmax 17.2 is shown in the right panel. Source data are provided as a Source Data file.
